Patents Examined by Catherine S Hibbert
  • Patent number: 10724051
    Abstract: A gene of interest and the gene encoding hypoxanthine-aminopterin-thymidine (HPRT) can be co-targeted for Casp9 nuclease-mediated editing or alteration in a cell. Based on whether the HPRT gene is altered to encode a non-functional protein, or is not so-altered, the co-targeted cells can be selected and counter-selected. HPRT co-targeting can be used to sequentially disrupt as many genes of interest as cell viability permits.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 28, 2020
    Assignee: Institute For Cancer Research
    Inventors: Hong Yan, Shuren Liao
  • Patent number: 10724043
    Abstract: Systems and methods are provided for transfecting immune competent cells with RNA at high efficiency and viability.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 28, 2020
    Assignee: NantBio, Inc.
    Inventors: Marcos Sixto, Kayvan Niazi, Ting Wu, Chihwei Chang
  • Patent number: 10724033
    Abstract: A method for selecting mammalian host cells that express a polypeptide of interest with high yield is described. The host cells comprise an expression cassette comprising at least a first polynucleotide encoding the polypeptide of interest, at least one leaky stop codon downstream of the first polynucleotide, and a second polynucleotide downstream of the leaky stop codon encoding an immunoglobulin transmembrane anchor. The host cells are cultivated to allow expression of the polypeptide of interest such that at least a portion of the polypeptide of interest is expressed as a fusion polypeptide that is displayed on the cell surface. The cells are selected based upon the presence or amount of the displayed fusion polypeptide. Also provided are methods for producing a polypeptide that employ a respective selection to identify high expressing host cells.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: July 28, 2020
    Assignee: Novartis AG
    Inventors: Thomas Jostock, Hans-Peter Knopf, Burkhard Wilms, Audrey Nommay
  • Patent number: 10717982
    Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E. coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: July 21, 2020
    Assignees: BioNTech RNA Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Florian Eberle, Ugur Sahin, Andreas Kuhn, Britta Vallazza, Mustafa Diken
  • Patent number: 10718001
    Abstract: Disclosed is a host cell for producing a recombinant peptide, polypeptide or protein of interest, wherein the host cell includes at least 2 copies of a nucleic acid sequence encoding a poison protein; and to the use thereof for producing peptides, polypeptides or proteins of interest.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 21, 2020
    Assignee: DELPHI GENETICS
    Inventors: Cedric Szpirer, Jonathan Cavrenne, Benjamin Michel
  • Patent number: 10718755
    Abstract: A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing N-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: July 21, 2020
    Assignee: WUHAN UNIVERSITY
    Inventor: Hongliang Li
  • Patent number: 10711279
    Abstract: The present invention relates to new promoter sequences and uses thereof, in particular expression cassettes, vectors, and methods of expressing genes using the new promoters.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: July 14, 2020
    Assignee: SANDOZ AG
    Inventors: Wolfgang Ernst, Jens Pontiller, Friedemann Hesse, Haruthai Thaisuchat
  • Patent number: 10711045
    Abstract: The invention discloses the use of an artificial protein for isolating a nucleosome, the nucleosome comprising a multiple-modified histone protein octamer, wherein the artificial protein comprises a first histone modification binding domain of 50 to 200 amino acids binding to a first histone modification, a second histone modification binding domain of 50 to 200 amino acids binding to a second histone modification, a linker of 5 to 50 amino acids connecting the first and the second histone modification binding domain, and an affinity tag. Further disclosed are a nucleic acid encoding the artificial protein, a host cell comprising the nucleic acid and a kit for isolating a nucleosome, the nucleosome comprising a multiple-modified histone protein octamer. Further disclosed is an in-vitro method for isolating a nucleosome having a first and a second histone modification.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: July 14, 2020
    Assignee: Universität Stuttgart
    Inventors: Albert Jeltsch, Goran Kungulovski, Rebekka Mauser
  • Patent number: 10676737
    Abstract: RNA editing is achieved using oligonucleotide constructs comprising (i) a targeting portion specific for a target nucleic acid sequence to be edited and (ii) a recruiting portion capable of binding and recruiting a nucleic acid editing entity naturally present in the cell. The nucleic acid editing entity, such as ADAR, is redirected to a preselected target site by means of the targeting portion, thereby promoting editing of preselected nucleotide residues in a region of the target RNA which corresponds to the targeting portion.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: June 9, 2020
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Bart Klein, Gerardus Johannes Platenburg
  • Patent number: 10669571
    Abstract: Provided herein are methods and compositions for depleting targeted nucleic acid sequences from a sample, enriching for sequences of interest from a sample, and/or partitioning of sequences from a sample. The methods and compositions are applicable to biological, clinical, forensic, and environmental samples.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 2, 2020
    Assignee: Arc Bio, LLC
    Inventors: Meredith L. Carpenter, Carlos D. Bustamante, Stephane B. Gourguechon
  • Patent number: 10648002
    Abstract: Methods of gene correction, methods of generating induced pluripotent stem cells (iPSCs), and methods of deriving multi-lineage cell types with therapeutic value. In some embodiments, the gene correction affects the expression and/or function of the functional type VII collagen protein (C7).
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 12, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Beau R. Webber, Mark J. Osborn, Jakub Tolar, Bruce R. Blazar
  • Patent number: 10647998
    Abstract: Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (ORF) for a protein under the control of regulatory sequences which direct expression of the product in cell, which ORF has been modified to preferentially increase expression levels in a selected tissue, wherein the modified ORF is characterized by a triplet frequency of any one of Tables 3-12, 16 or 17.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 12, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Anna Tretiakova
  • Patent number: 10633689
    Abstract: Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cells under conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying the prenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: April 28, 2020
    Assignee: SPARK THERAPEUTICS, INC.
    Inventors: John Fraser Wright, Marina Sumaroka
  • Patent number: 10626415
    Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Luk Vandenberghe, Guangping Gao, James M. Wilson
  • Patent number: 10619155
    Abstract: The invention relates to methods and kits for labeling and manipulating a cellular circuit. The methods includes transfecting a first-order cell in the cellular circuit with a nucleic acid molecule encoding a tethered ligand, and a second-order cell in the cellular circuit with a nucleic acid molecule encoding a receptor and an effector fusion polypeptide, a nucleic acid molecule encoding a receptor interactor and protease fusion polypeptide, and a nucleic acid molecule encoding a reporter/modifier gene.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 14, 2020
    Assignee: BROWN UNIVERSITY
    Inventors: Gilad Barnea, Mustafa Talay, Ethan Richman, John Szymanski, Mark Johnson, John Fisher, Nathaniel Snell
  • Patent number: 10614353
    Abstract: Described herein are novel biological converter switches that utilize modular components, such as genetic toggle switches and single invertase memory modules (SIMMs), for converting analog inputs to digital outputs, and digital inputs to analog outputs, in cells and cellular systems. Flexibility in these biological converter switches is provided by combining individual modular components, i.e., SIMMs and genetic toggle switches, together. These biological converter switches can be combined in a variety of network topologies to create circuits that act, for example, as switchboards, and regulate the production of an output product(s) based on the combination and nature of input signals received.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: April 7, 2020
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: James J. Collins, Timothy Kuan-Ta Lu
  • Patent number: 10612030
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: April 7, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Patent number: 10607716
    Abstract: Methods for design of genetic circuits are provided.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: March 31, 2020
    Assignee: The Regents of the University of California
    Inventors: Chunbo Lou, Tae Seok Moon, Virgil Rhodius, Brynne Stanton, Alvin Tamsir, Karsten Temme, Chris Voigt
  • Patent number: 10597648
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: March 24, 2020
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10590435
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 17, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira